TY - STD TI - World Health Organization: Cardiovascular Diseases (CVDs): Fact sheet N°317. 2013. http://www.who.int/mediacentre/factsheets/fs317/en/ UR - http://www.who.int/mediacentre/factsheets/fs317/en/ ID - ref1 ER - TY - JOUR AU - Phan, B. A. P. AU - Dayspring, T. D. AU - Toth, P. P. PY - 2012 DA - 2012// TI - Ezetimibe therapy: mechanism of action and clinical update JO - Vasc Health Risk Manag VL - 8 ID - Phan2012 ER - TY - JOUR AU - Cannon, C. P. AU - Braunwald, E. AU - McCabe, C. H. AU - Rader, D. J. AU - Rouleau, J. L. AU - Belder, R. PY - 2004 DA - 2004// TI - Intensive versus moderate lipid lowering with statins after acute coronary syndromes JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa040583 DO - 10.1056/NEJMoa040583 ID - Cannon2004 ER - TY - JOUR AU - Kastelein, J. J. P. AU - Akdim, F. AU - Stroes, E. S. G. AU - Zwinderman, A. H. AU - Bots, M. L. AU - Stalenhoef, A. F. H. PY - 2008 DA - 2008// TI - Simvastatin with or without ezetimibe in familial hypercholesterolemia JO - N Engl J Med VL - 358 UR - https://doi.org/10.1056/NEJMoa0800742 DO - 10.1056/NEJMoa0800742 ID - Kastelein2008 ER - TY - JOUR AU - Blazing, M. A. AU - Giugliano, R. P. AU - Cannon, C. P. AU - Musliner, T. A. AU - Tershakovec, A. M. AU - White, J. A. PY - 2014 DA - 2014// TI - Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population JO - Am Heart J VL - 168 UR - https://doi.org/10.1016/j.ahj.2014.05.004 DO - 10.1016/j.ahj.2014.05.004 ID - Blazing2014 ER - TY - JOUR PY - 2014 DA - 2014// TI - Inactivating mutations in NPC1L1 and protection from coronary heart disease JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1405386 DO - 10.1056/NEJMoa1405386 ID - ref6 ER - TY - STD TI - Khoury M, Bedrosian S, Gwinn M, Higgins J, Ioannidis J, Little J. Human genome epidemiology. 2nd ed. Oxford University Press; 2010. ID - ref7 ER - TY - JOUR PY - 2012 DA - 2012// TI - The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis JO - Lancet VL - 379 UR - https://doi.org/10.1016/S0140-6736(12)60110-X DO - 10.1016/S0140-6736(12)60110-X ID - ref8 ER - TY - STD TI - Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2014. doi: 10.1016/S0140-6736(14)61183-1. ID - ref9 ER - TY - JOUR AU - Ference, B. A. AU - Majeed, F. AU - Brook, R. D. AU - Hedquist, L. AU - Penumetcha, R. AU - Flack, J. M. PY - 2014 DA - 2014// TI - Effect of naturally random allocation to lower LDL-C mediated by polymorphisms in NPC1L1, HMGCR or both on the risk of coronary heart disease: a 2x2 factorial Mendelian randomization study [abstract] JO - Circulation VL - 130 ID - Ference2014 ER -